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Epstein–Barr virus (EBV) is a ubiquitous human γ-herpes virus which establishes a life-long
asymptomatic infection in immunocompetent hosts. In human immunodeﬁciency virus
type 1 (HIV-1) infected patients, the impaired immunosurveillance against EBV may favor
the development of EBV-related diseases, ranging from lymphoproliferative disorders to B
cell non-Hodgkin’s lymphomas (NHL). Antiretroviral therapy (ART) has signiﬁcantly modiﬁed
the natural course of HIV-1 infection, resulting in decreased HIV-1 plasmaviremia, increased
CD4 lymphocytes, and decreased opportunistic infections, indicating a restoration of
immune functions. However, the impact of ART appears to be less favorable on EBV-related
malignancies than on other AIDS-deﬁning tumors, such as Kaposi’s sarcoma, and NHL
remains the most common cancer during the ART era. EBV-driven tumors are associated
with selective expression of latent oncogenic proteins, but uncontrolled lytic cycle with
virus replication and/or reactivation may favor cell transformation, at least in the early
phases. Several host’s factors may promote EBV reactivation and replication; besides
immunodepression, inﬂammation/chronic immune stimulation may play an important role.
Microbial pathogen-associated molecular patterns and endogenous damage-associated
molecular patterns, through Toll-like receptors, activate the immune system and may
promote EBV reactivation and/or polyclonal expansion of EBV-infected cells. A body of
evidence suggests that chronic immune stimulation is a hallmark of HIV-1 pathogenesis
and may persist even in ART-treated patients. This review focuses on lymphomagenesis
driven by EBV both in the context of the natural history of HIV-1 infection and in ART-treated
patients. Understanding the mechanisms involved in the expansion of EBV-infected cells
is a premise for the identiﬁcation of prognostic markers of EBV-associated malignancies.
Keywords: EBV,HIV-1, B cell activation, chronic immune activation, EBV-relatedmalignancies, antiretroviral therapy,
EBV lytic reactivation
INTRODUCTION
Epstein–Barr virus (EBV) is a ubiquitous human γ-herpes virus
which establishes a life-long asymptomatic infection in immuno-
competent hosts. Most individuals contract EBV infection by early
adulthood; primary EBV infection is usually asymptomatic, but
sometimes results in infectious mononucleosis, a self-limiting dis-
ease due to the EBV-speciﬁc immunological response. Regardless
of its iatrogenic or infectious origin, immunodeﬁciency increases
the risk of tumor development, particularly of tumors etiolog-
ically linked to viral agents. In post-transplant patients and in
individuals infected with human immunodeﬁciency virus type 1
(HIV-1), impaired immunosurveillance against EBV may favor
the development of EBV-associated diseases, ranging from lym-
phoproliferative disorders to B cell non-Hodgkin’s lymphomas
(NHL; Ometto et al., 1997; Beral and Newton, 1998). Antiretro-
viral therapy (ART) partially restores immune functions and has
signiﬁcantly changed the course of HIV-1 infection (Palella et al.,
1998). However, the impact of ART seems to be less favorable on
EBV-related diseases than on other AIDS-deﬁning events, includ-
ing Kaposi’s sarcoma (KS; Simard et al., 2011). Notably, NHL has
been considered as an AIDS-deﬁning cancer (ADC) since 1985,
and remains one of the main causes of death in HIV-1 infected
patients even in the ART era [Collaboration of Observational HIV
Epidemiological Research Europe (COHERE) Study Group, 2009;
Simard et al., 2011].
INCIDENCE OF EBV-RELATED MALIGNANCIES IN HIV-1
INFECTED PATIENTS
There are several subtypes of AIDS-associated NHL, including
Burkitt’s lymphoma (BL), immunoblastic lymphoma (IBL), dif-
fuse large B cell lymphoma (DLBCL), and primary central nervous
system lymphoma (PCNSL). The frequency of EBV detection in
these tumors ranges from 60% in BL to 100% in PCNSL (Carbone
et al., 2009). Before the introduction of ART, the incidence of NHL
in HIV-1 infected subjects was 100 times higher than in the gen-
eral population (Goedert et al., 1998; International Collaboration
on HIV and Cancer, 2000), PCNSL and high grade IBL being the
most common NHL subtypes, followed by BL and intermediate
grade DLBCL (Kaplan, 2012).
High levels of HIV-1 plasmaviremia and low CD4 cell counts
are both risk factors for the onset of NHL. The risk substantially
increases in patients with>100,000 HIV-1 RNA copies/ml and/or
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with <50 CD4 cells/μl (Engels et al., 2010). However, systemic
lymphomas may occur at virtually any level of CD4 cell count, BL
occurring more frequently in patients with moderate/advanced
immunodepression (200–500 CD4 cells/μl) and PCNSL occur-
ring in patients with severe immunodepression (<200 CD4
cells/μl).
The introduction of ART into clinical practice has modiﬁed the
natural course of HIV-1 infection, resulting in the decrease of HIV-
1 plasmaviremia, increase in CD4 T lymphocytes, and decrease
in HIV-1-associated opportunistic infections. Deaths from AIDS-
related diseases have fallen by 75% (Tirelli and Bernardi, 2001) and
people diagnosed with HIV-1 can expect to live for 30 or 40 years
after contracting the infection, equivalent to a reduction in lifespan
of about one-third (Grulich,2009). Therefore, patientswithHIV-1
infection are now living longer, with improved immune functions
and reduced risk of developing AIDS; nevertheless, ADCs remain
higher when compared with the rate of these cancers in the general
population (Petoumenos et al., 2013).
After the introduction of ART, the overall incidence of NHL
declined by nearly 50% compared with ART-untreated patients
(International Collaboration on HIV and Cancer, 2000; Biggar
et al., 2007; Simard et al., 2011); the adjusted incidence rate of
NHL was estimated to decline from 6.2% pre-ART (1992–1999)
to 3.2% in the ART era (1997–1999; International Collabora-
tion on HIV and Cancer, 2000). Five-year cumulative incidence
of NHL declined from 3.8% during the 1990–1995 period to
2.2% during 1996–2006 (Simard et al., 2011). This pattern is quite
different from that observed with KS, associated with human her-
pes virus 8 (HHV8; Cattelan et al., 1999; Simard et al., 2011).
The adjusted incidence rate of KS declined from 14.3% pre-
ART to 1.8% in the ART era (Simard et al., 2011). After the
introduction of ART, NHL is still the most common ADC. In
addition, the decline is not equally distributed among the various
NHL subtypes, but is higher for PCNSL and lower for the other
subtypes.
The increased risk of NHL cannot be explained by immun-
odepression alone. Patients treated with ART may survive longer,
with continued B cell stimulation, leading to an increased inci-
dence of lymphoma over time. Emerging data also indicate that
HIV-1 infection, even among long-term ART-treated patients, is
associated with a higher rate of non-AIDS-deﬁning malignan-
cies (NADC; Deeken et al., 2012); this evidence further supports
the concept that immunodeﬁciency is not sufﬁcient to explain
the higher risk of cancer in HIV-1 infected subjects. The sub-
stantial reduction in HIV-1-associated mortality and the increase
in an aging population with HIV-1 may contribute to the rise in
NADC, including some tumors associated with co-infections [e.g.,
anal and oropharyngeal cancer associated with human papillo-
mavirus, liver cancer associated with hepatitis B and C viruses,
and Hodgkin’s lymphoma (HL) associated with EBV]. In a cohort
of HIV-1 infected European patients, the incidence of HL was
4.5 times higher than in the general population pre-ART (1983–
1985) and 32 times higher in the ART era (2002–2007; Powles
et al., 2009). These results have been replicated in a Swiss HIV-1
cohort, in which the incidence of HL increased 9 times pre-ART,
21 times in the early ART era, and 28 times in the late ART
era (Franceschi et al., 2010). Also, in a United States cohort, the
5-year cumulative incidence of HL increased from 0.09% pre-
ART (1980–1989) to 0.19% in the ART era (1996–2006; Simard
et al., 2011). HIV-1-associated HL differs from HL in HIV-1 unin-
fected patients, because it is almost always associated with EBV
and more often presents systemic “B” symptoms, and extranodal
involvement (Jacobson and Abramson, 2012).
EBV-DRIVEN TUMORIGENESIS
Epstein–Barr virus is associated with both B cell and epithelial
cell malignancies. Like all herpes viruses, EBV has both latent and
lytic replication programs, allowing it to evade immune clearance
and persist for the host’s lifetime. Latent infection is characterized
by replication of the viral genome as an integral part of the host
cell chromosomes and the absence of production of infectious
virus. Since lytic EBV replication triggers the death of infected
cells, tumors require the expression of latent programs. Latent
proteins include nuclear antigens (EBNA-1, -2, -3A, -3B, and -
3C), leader protein (LP), and latent membrane proteins (LMP-1,
-2A, and -2B). LMP-1 is the main oncogenic protein of EBV and is
essential for EBV-driven tumorigenesis. It is expressed in all NHL,
except BL, and also in HL. Functionally, LMP-1 mimics CD40,
a member of the tumor necrosis factor receptor (TNFR) super-
family, thus providing both growth and differentiation signals to
B cells. LMP-1 does in fact activate several downstream signaling
pathways which contribute to the induction of genes encoding
anti-apoptotic proteins (e.g., BCL-2 and A20) and cytokines, such
as interleukin (IL)-1, and CD40L (Young and Rickinson, 2004;
Chen, 2011).
In vitro, EBV infection of B cells may generate immortalized
lymphoblastoid B cell lines (LCL) which express all the latent viral
genes, as most EBV-NHL do; this is why LCL are often employed
as a model to study EBV-driven lymphomagenesis. Besides the
expression of viral latent proteins, the transformation of pri-
mary B lymphocytes by EBV requires the activation of telomerase
(Dolcetti and De Rossi, 2012). Telomerase is a ribonucleoprotein
complex, containing an internal RNA, used as a template to elon-
gate telomeres, and a catalytic protein with telomerase reverse
transcriptase (TERT) activity. Telomerase is critically involved in
maintaining telomere length and its activation is required for
cells to overcome replicative senescence and acquire unlimited
replicative potential, a prerequisite for neoplastic transformation
(Blackburn et al., 2006). It has been demonstrated that LMP-1
activates TERT at transcriptional level via nuclear factor kappa B
(NF-κB) and MAPK/ERK1/2 pathways (Terrin et al., 2007, 2008).
In turn, TERT expression confers resistance to apoptotic stimuli
and to the induction of the lytic cycle (Giunco et al., 2013).
Although latency programs predominate in EBV-driven
tumors, recent evidence suggests that lytic EBV replication has
some pathogenic importance, at least in the early phases of cell
transformation. Several lytic proteins expressed during the lytic
cycle of infection are involved in immune evasion. They include
the BCRF-1 gene which encodes a viral IL-10 cytokine which, like
human IL-10, inhibits the synthesis of interferon-γ (IFN-γ) and
suppresses CD8 cytotoxic T cell (Draborg et al., 2012). Recent
studies also suggest that the lytic cycle contributes to the growth of
EBV-associated malignancies by enhancing angiogenesis. Indeed,
B cells infected with a virus competent for the expression of the
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lytic protein BZLF-1 released more vascular endothelial growth
factor and IL-6 than cells infected with BZLF-1-defective virus
(Hong et al., 2005). A new humanized mouse model, in which
both human fetal CD34 hematopoietic stem cells and thymus/liver
tissue were transplanted, was employed to test EBV-driven
lymphomagenesis; mice injected with lytic replication-defective
BZLF1-deleted virus developed fewer lymphomas than animals
infected with lytic BZLF1-competent virus, suggesting that lyt-
ically infected cells promote EBV-driven lymphomagenesis (Ma
et al., 2011).
DIRECT AND INDIRECT INTERACTIONS OF HIV-1 WITH B
CELLS AND EBV
Besides impaired immunosurveillance against EBV-infected cells
due to the loss of T cell function, HIV-1 may contribute to the
genesis of EBV-associated NHL through chronic B cell hyperac-
tivation. Chronic systemic immune activation is a hallmark of
HIV-1 pathogenesis; being one of the strongest predictors of dis-
ease progression (Deeks et al., 2004; Hunt et al., 2008) and it is
also associated with impaired immune reconstitution during ART
(Anselmi et al., 2007).
Immune activation involves both T cell and B cell compart-
ments. In the former, immune activation may be assessed by
the high frequency of T cells expressing markers of activation,
such as CD38 and HLA-DR (Hazenberg et al., 2000; Anselmi
et al., 2007), high levels of T cell proliferation (Hellerstein et al.,
2003), and activation-induced apoptosis of HIV-1 uninfected T
cells (Gougeon et al., 1996). In the B cell compartment, B cells
express high levels of CD80 and CD86 co-stimulatory molecules.
Several changes in the B cell subsets have also been described in
association with HIV-1 plasmaviremia and/or CD4 cell decline.
These changes include an increase in activated (CD27+CD21low)
and exhausted (CD27−CD21low) B cells (Moir and Fauci, 2009),
a decrease in circulating memory (CD27+) B cells (Titanji et al.,
2006), and an increase in immature/transitional (CD27−CD10+)
B cells (Malaspina et al., 2006). Immune activation may result in
polyclonal B cell activation, hypergammaglobulinemia, increased
cell turnover (Moir and Fauci, 2009), and ultimately increased
frequency of B cell malignancies (Grulich et al., 2000).
The factors contributing to B cell hyperactivation and expan-
sion of EBV-infected B cells remain largely unknown. The
mechanisms responsible for polyclonal B cell activation seem to
be multiple, and due to a combination of both direct and indi-
rect interaction of B cells with HIV-1. HIV-1 itself can induce
polyclonal B cell activation in vitro (Schnittman et al., 1986).
It has been demonstrated that CD40L is incorporated into the
HIV-1 envelope (Ambinder et al., 2010), and that B cells derived
from the peripheral blood of HIV-1 infected viremic patients
carry replication-competent virus on their membrane (Moir et al.,
2000). There is evidence that HIV-1 binds to B cells through
interactions between the complement receptor CD21, which is
expressed on most mature B cells (Moir et al., 2000); the virus
bound to B cells can efﬁciently infect CD4 T cells through cell–
cell contact (Malaspina et al., 2002). A model of “self-limiting”
HIV-1 infection of B cells has been described. After in vitro
exposure to HIV-1, a steady-state fraction of LCL resulted pos-
itive for HIV-1 gp120 envelope protein. These cells underwent
down-regulation of BCL-2 and death by apoptosis; the persistent
fraction of gp120+ cells was maintained by HIV-1 transmission
to B cells newly arising from the proliferation of gp120− cells (De
Rossi et al., 1994). It was also demonstrated that a fraction of B
cells may bind gp120 through mannose C-type lectin receptors
(MCLRs). In the presence of gp120, MCLR-expressing B cells up-
regulate the activation-induced cytidine deaminase, and undergo
immunoglobulin class switching (He et al., 2006). By contrast,
HIV-1proteinNef suppresses class switch recombinationonBcells
by interfering with CD40L-mediated signaling (Qiao et al., 2006).
Nef also promotes polyclonal B cell activation and increases CD4T
cell susceptibility to HIV-1 infection by inducing macrophages to
secrete pro-inﬂammatory cytokines (Swingler et al., 2008). Addi-
tional in vitro evidence of direct interaction between HIV-1 and
several receptors on B cells have been reported (Berberian et al.,
1993; Rappocciolo et al., 2006), however, to date there is still
little evidence that HIV-1 can productively replicate in B cells
in vivo.
The transactivator Tat protein of HIV-1 is released by HIV-1
infected cells and is taken up by surrounding HIV-1-uninfected
cells through interactions with cell membrane heparan sulfate
proteoglycans (Frankel and Pabo, 1988; Tyagi et al., 2001). HIV-1
binds to B cells which are in close contact with HIV-1-infected
macrophages and to dendritic cells in the extranodal sites where
NHL usually occur (Sparano, 2001). This cell–cell contact may
favor B cell uptake of the protein; Tat protein has in fact been con-
sistently detected in the neoplastic cells of NHLoccurring inHIV-1
infected subjects (Lazzi et al., 2002). Tat modulates the expression
of several cellular genes, including cytokines and their receptors,
and increases the expression of IL-6 and IL-10 (Scala et al., 1994;
Blazevic et al., 1996), which in turn promote B cell activation. It
has been demonstrated that Tat prevents cell cycle arrest and con-
fers resistance to apoptosis in EBV-infected B cells cultured in vitro
in serum starvation conditions (Colombrino et al., 2004).
Chronic B cell hyperactivation is driven by overproduction
of B cell stimulatory cytokines, such as IL-6, IL-10, interferon-
α (IFN-α), and tumor necrosis factor (TNF; Rieckmann et al.,
1991; Takeshita et al., 1995; Mandl et al., 2008). The serum levels
of these B cell stimulatory cytokines and other molecules, such
as soluble sCD27 and sCD30 generated from the corresponding B
cell receptors during the process of immune activation, were sig-
niﬁcantly high 1–5 years prior to diagnosis of systemic AIDS-NHL
(Ambinder et al., 2010; Breen et al., 2011). Elevated serum levels of
IL-6 have also been observed 1–3 years prior to the onset of AIDS-
NHL, thus supporting the role of IL-6-driven B cell stimulation in
the development of these lymphomas (Breen et al., 2011).
Lastly, an important source of immune activation in HIV-1
infected individuals is provided by microbial translocation due to
damage to intestinal mucosa caused by massive HIV-1-induced T
cell depletion in the gut (Brenchley et al., 2006). Translocation of
intestinal bacteria and bacterial products into the bloodstream can
activate the immune systemby binding to receptors involved in the
host inﬂammatory response, such as Toll-like receptors (TLRs).
TLRs are pattern recognition receptors which recognize struc-
tural components belonging to bacteria, fungi, and viruses, known
as “pathogen-associated molecular patterns” (PAMPs), and acti-
vate the innate immune response (Janeway and Medzhitov, 2002).
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PAMPs include bacterial lipopolysaccharide (LPS), 16S ribosomal
DNA (16S rDNA), and CpG DNA. A recent study demonstrated
that levels of PAMPs, generated bymicrobial translocation (sCD14
and LPS) are associated with the risk of NHL (Marks et al., 2013).
TLR9 substantially suppresses BZLF-1-mRNA expression by his-
tonemodiﬁcations in acute EBV infection ex vivo and in latently BL
cells in vitro, suggesting that immune activation can also promote
EBV-driven lymphomagenesis by suppressing the viral lytic cycle
(Ladell et al., 2007). Patients who developed PCNSL expressed
more CD80 and CD86 in their B cells and responded to TLR9
agonist better than patients without tumors (Audigé et al., 2010).
The loss of mucosal surface integrity in the gut, due to the mas-
sive depletion of CD4 T cells, involves not only increased mucosal
permeability and consequent microbial translocation, but also
an increase in “damage-associated molecular patterns” (DAMPs),
endogenous molecules released after cell death, such as mitochon-
drial DNA (mtDNA; Zhang et al., 2010), high mobility group box
1 (HMGB1) protein (Scafﬁdi et al., 2002) and defensins (Sørensen
et al., 2005). The binding of PAMP andDAMP ligands to the extra-
or intra-cellular domain of TLRs initiates a complex-signal trans-
duction cascade which, via the NF-κB pathway, ultimately leads
to increased transcription of pro-inﬂammatory cytokines, such as
IL-6 and TNF. During chronic infection, PAMPs and DAMPs may
act in synergy on the TLR response. Thus, chronic inﬂammation
may favor an environment which triggers tumor development.
IMPACT OF ANTIRETROVIRAL THERAPY ON EBV
LYMPHOMAGENESIS
The impact of ART is less favorable on EBV-related malignancies
than on other ADC. In addition, the decline after the introduction
of ART was more substantial in PCNSL than in other NHL sub-
types. Because of the role played by chronic immune activation in
the genesis of NHL, itmay be argue that thismechanism (partially)
persists even during ART. A study performed on a cohort of HIV-
1-infected patients under ART disclosed a decline in both EBV
plasmaviremia and citoviremia in patients with immunological
(increase in CD4 cells) and virological (decline in HIV-1 plas-
maviremia to undetectable levels) responses. Notably, a decrease
in EBV load was also detected in patients with only virological
response to ART. By contrast, the increase in CD4 cells with-
out suppression of HIV-1 plasmaviremia was accompanied by an
increase in EBV load, paralleled by an increase in immunoglobu-
lin levels (Righetti et al., 2002). In agreement, EBV-DNA load was
higher in patients with detectable HIV-1 plasmaviremia, despite
good immunological status (>500 CD4 cells/μl) than in patients
with undetectable HIV-1 plasmaviremia, regardless of immuno-
logical status (Petrara et al., 2012). It has been observed that ART
only partially normalizes the serum cytokine levels; IL-6 remain
at high levels even 2–3 years after ART initiation (Regidor et al.,
2011). These ﬁndings strongly suggest that immune reconstitu-
tion without reduction in HIV-1 viremia may increase B cell
stimulation and the number of EBV-infected cells; this may be
important for new therapeutic strategies against HIV-1 to imple-
ment immune reconstitution and/or to alleviate adverse drug
effects.
HIV-1 infected patients, treated with ART in combination with
IL-2 to improve immunological reconstitution, showed a decrease
in EBV plasmaviremia and citoviremia when treated with low-
intermittent IL-2 doses, but presented an increase in EBV in both
cells and plasma when treated with high doses of IL-2 (Burighel
Table 1 | Factors involved in HIV-1 and EBV interplay through B cell activation.
Factors Mechanism(s) Reference
HIV-1 proteins Virions Virions bind to B cells through CD21 and transmit infection to T cells Moir et al. (2000)
gp120 Binding to C-type lectins and induced immunoglobulin class switch recombination
through a CD40-independent mechanism
He et al. (2006)
Induction of TNF-α and hypergammaglobulinemia Rieckmann et al. (1991)
gp120 (X4 strains) Increased proliferation capability of EBV+ B cells Iyengar and Schwartz (2011)
gp41 Induced activation of IL-6 and IL-10 pro-inﬂammatory cytokines Takeshita et al. (1995)
Nef Activation of B cells and induction of hypergammaglobulinemia through ferritin
produced via Nef-mediated activation of NF-κB
Swingler et al. (2008)
Suppression of CD40-dependent immunoglobulin class switching Qiao et al. (2006)
Tat Binding to Rb2/p130 and induction of cell cycle genes; modulation of cell cycle and
increased proliferative capability of EBV+ B cells
Lazzi et al. (2002);
Colombrino et al. (2004)
PAMPs∗ LPS Engagement and activation of TLR4; induction of pro-inﬂammatory cytokines Brenchley et al. (2006)
16S rDNA, CpG DNA Engagement and activation of TLR9; suppression of EBV lytic cycle through
inhibition of BZLF expression
Ladell et al. (2007);
Zauner and Nadal (2012)
DAMPs∗∗ mtDNA Engagement of TLR9 and suppression of EBV lytic cycle Zhang et al. (2010)
HMGB1 Engagement of TLR2 andTLR4; induction of pro-inﬂammatory cytokines Scafﬁdi et al. (2002)
∗Pathogen-associated molecular patterns.
∗∗Damage-associated molecular patterns.
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et al., 2006). Thus, according to dose, IL-2 may signiﬁcantly affect
EBV dynamics. Low doses of IL-2, by binding to high-afﬁnity
receptors expressed on T lymphocytes, may promote the activity
of cytotoxic T lymphocytes, thus restoring protective immunity
against EBV.Notably, lowdoses of IL-2 prevented the development
of EBV-associated disease in severe combined immunodeﬁciency
(SCID) mice reconstituted with peripheral blood cells from EBV-
seropositive subjects (Baiocchi and Caligiuri, 1994). Conversely,
high doses of IL-2, by binding low-afﬁnity receptors expressed on
natural killer (NK) cells, may enhance several pro-inﬂammatory
cytokines, and consequently B cell stimulation and activation
(Jacobson et al., 1996; Malnati et al., 2002; Table 1).
It has been demonstrated that patients with high levels of EBV
have higher levels of pro-inﬂammatory cytokines (IL-6, IL-10,
TNF-α) and PAMPs (LPS) than patients with low EBV level, and
that EBV load strongly correlateswith the percentage of activatedB
cells (Petrara et al., 2012). In addition, patients under CD4-guided
interruption of ART to reduce adverse drug effects show simi-
lar levels of HIV-1 plasmaviremia to ART-untreated patients and
high levels of EBV (Petrara et al., 2012). The association between
markers of B cell activation and the risk of NHL persists even
after adjustment for CD4 T cell count, HIV-1 load and ART, thus
supporting the independent role of these markers with NHL risk
(Guiguet et al., 2009; Engels et al., 2010; Marks et al., 2013). These
FIGURE 1 | Mechanisms potentially contributing to polyclonal B cell
activation and expansion of EBV-infected B cells in HIV-1 infected
patients. HIV-1 acts as both a direct or indirect activator of B cells. Direct
effects of HIV-1 include binding to B cells of HIV-1 viral proteins, such as
gp120, Tat, and Nef, promoting polyclonal B cell activation. Indirect effects
result from HIV-1-induced immune activation. Breakdown of gut mucosa
induced by HIV-1 antigens increases intestinal permeability, resulting in
translocation of microbial products. Pathogen-associated molecular patterns
(PAMPs), such as LPS, 16S rDNA, and CpG DNA, and endogenous molecules
created upon tissue injury (damage-associated molecular patterns, DAMPs),
such as mitochondrial DNA (mtDNA), defensins and high mobility group box 1
(HMGB1) protein, by engagingToll-like receptors (TLRs) activate signaling
cascade leading to increased transcription of pro-inﬂammatory cytokines. In
this context, both EBV-infected and uninfected B cells are activated and may
undergo proliferation; EBV-infected cells may overcome uninfected ones due
to higher replicative capacity and telomerase activation.
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ﬁndings additionally support the concept that B cell activation,
regardless of CD4 immune reconstitution, favors expansion of
EBV-infected cells and the onset of EBV-related malignancies.
CONCLUDING REMARKS
The risk of EBV-associated NHL in HIV-1 infected patients com-
pared with the general population is mainly increased by impaired
immunosurveillance against EBV and B cell chronic immune acti-
vation. The two mechanisms may contribute to the development
of NHL subtypes in different ways. InHIV-1 infected subjects with
lowCD4Tcell count and severe immunedepression, a notable pro-
portion of NHL is represented by PCNSL. These tumors are almost
100%EBV-positive, are less signiﬁcantly linked to circulating levels
of pro-inﬂammatory cytokines than systemic NHL (Breen et al.,
2011), and represent the NHL subtype which most signiﬁcantly
declined after the introduction of ART. These observations are
consistent with the concept that PCNSL primarily results from the
loss of immunosurveillance against EBV.
Systemic HL may occur relatively early in HIV-1 disease and
the impact of ART in reducing these tumors is lower than that
observed for PCNSL and other ADC. Chronic immune activation
may considerably affect the onset of systemic NHL; chronic B
cell activation, generated by HIV-1 antigens and the products of
microbial translocations, may result in expansion of B cells and
accumulation of genetic lesions over a prolonged period of time.
According to this model, EBV does not represent a prerequisite for
systemic lymphomagenesis; unlike PCNSL, systemic lymphomas
may also be EBV-negative. Nonetheless, the oncogenic properties
of EBV play a critical role; EBV-infected B cells may overcome
EBV-negative B cells due to the proliferating activity and activa-
tion of telomerase (Terrin et al., 2007, 2008; Dolcetti and De Rossi,
2012); most systemic tumors are in fact EBV-positive (Figure 1).
Current strategies to treat HIV-1 are efﬁcient in decreasing HIV-1
plasmaviremia and restoring immune functions but may be not
efﬁcient enough in reducing immune activation (Regidor et al.,
2011). The new strategies to treat HIV-1 should take into account
this important parameter. The prevention of chronic immune
activation may prevent the onset of EBV-related diseases.
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